Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

BOB.V, PWRM, PLUS, PUDA, ITMN - Market Report From DrStockPick.com!

drstock-2-3

signup3m


power3

Power3 Medical Products, Inc. (OTC.BB:PWRM) business focus is the development of commercial applications for their proprietary technologies. The scientific team is on the leading edge of the proteomics industry through their discovery of protein footprints, pathways, and mechanisms of disease. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer, neurodegenerative disease and drug resistance in cancer. The Company is in a strong competitive position with over 190 identified biomarkers and a state-of-the-art proteomics laboratory.

Alzheimer's disease is among the most well known form of dementia, a broad term when it comes to forgetfulness and other intellectual abilities critical enough to obstruct everyday life. Alzheimer's diseases is the reason for 50 to seventy per cent of dementia cases.

Soon after cancer of the skin, cancer of the breast is easily the most well-known cancer diagnosis in females in the USA. However, breast cancer rates currently have gone down these days, though doctors aren’t certain why. Even now, for many women, breast cancer may be the health probem that they fear most.

Parkinson’s disease is really a problem that affects nerve cells, or neurons, inside of a section of the brain of which controls muscle motions. In Parkinson’s, nerves which make an important chemical called dopamine die or do not work properly. Dopamine generally delivers impulses that assist synchronize a person’s activities.

******************************************

http://pennyomega.com/img/bob.jpg

Global Hunter Corp.'s (TSX.V: BOB) (FSE:G5D) focus is on strategic and base metals, particularly copper and molybdenum. The Company has built an outstanding portfolio of projects in the stable geopolitical geographies of Canada and Chile. Our exploration and development teams are on the ground rapidly advancing the La Corona de Cobre property near La Serena, Chile and the Rabbit South property in British Columbia, Canada. Either one of these projects could carry the company forward on a stand-alone basis, but together they bring the company additional stability, strength and value.

Global Hunter's La Corona de Cobre project is over 18,000 hectares of land located in the Coast Range of the Andean Cordillera, Chile, an area often referred to as the Chilean Iron Belt. The property is on the Pan American Highway, 70-kilometres north of the port city La Serena.

Global Hunter's Rabbit South molybdenum project is located within a prolific mining region in the Dominic and Roper Lake area, 27 kilometres west-southwest of the city of Kamloops British Columbia. The property is accessible year round by a combination of highway and logging roads. Rabbit South is situated 25 kilometres northeast of Highland Valley, BC's largest porphyry copper mine (1.4 billion tonnes @ 0.40% Cu) and 12 kilometres southwest of Afton, BC's richest porphyry copper mine (107Mi tonnes @ 1.05% Cu, 0.70g/t Au).

Global Hunter Corp. engages in the acquisition, exploration, and development of mineral properties in Canada and Chile. It primarily explores for gold, copper, and base and precious metals. The company was founded in 1988 and is headquartered in Vancouver, Canada.

For More Information Go To: www.globalhunter.ca

******************************************

ePlus Inc. (Nasdaq:PLUS) announced on that its wholly owned subsidiary, ePlus Technology, inc., has been recognized by Everything Channel’s CRN Magazine as one of the Top Healthcare VARs.

ePlus inc., through its subsidiaries, engages in selling, leasing, financing, and managing information technology (NYSE:IT) and other assets in the United States. It involves in direct marketing of IT equipment and third-party software, as well as offers professional and business process services.

******************************************

Puda Coal Inc. (AMEX: PUDA) announced that it has completed and closed its public offering of 9 million shares of common stock at a public offering price of $12 per share, including 7.85 million primary shares sold in the closing on December 13, 2010 and an additional 1.15 million shares pursuant to the underwriters’ exercise of an over-allotment option on December 16, 2010.

Puda Coal, Inc., through its indirect equity ownership in Shanxi Puda Coal Group Co., Ltd., supplies metallurgical coking coal to the industrial sector in the People’s Republic of China. Its processed coking coal is used by coke and steel producers for the purpose of making the coke required for the steel manufacturing process.

******************************************

InterMune Inc. (Nasdaq:ITMN) announced additions to its senior leadership team to prepare for the commercialization of Esbriet™ (pirfenidone) in Europe. InterMune’s Marketing Authorization Application (NYSE:MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.

InterMune, Inc., a biotech company, focuses on developing and commercializing therapies in pulmonology and hepatology primarily in the United States and Europe. The company primarily offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease.

***************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

drstbc

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).

Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty-five thousand dollars in cash from Global Hunter Corp. (TSX Venture Exchange (TSX.V:BOB) and the Frankfurt Stock Exchange (FSE:G5D)) for 30 (thirty) days of advertising, as well as for assistance in becoming a fully reporting publicly trading Bulletin Board company.